Sam's News — health — 2026-09-04¶
Healthcare¶
7.5 Novartis Cardiovascular Drug Fails Pivotal Study¶
Novartis announced September 4, 2026, that pelacarsen, an experimental cardiovascular drug, failed its pivotal Phase 3 HORIZON trial. Despite earlier success in lowering Lp(a) levels, the drug did not reduce cardiovascular death or acute cardiovascular events compared to placebo.
- Phase 3 HORIZON trial failed September 4, 2026
- Earlier trials showed pelacarsen significantly lowered Lp(a), a lipid-protein linked to heart disease
- Failed to reduce risk of cardiovascular death or acute events (heart attacks, stroke) vs. placebo
- Competitors Amgen and Eli Lilly also developing Lp(a)-targeting therapies
Sources: STAT News AI Web Searched
Health¶
5 Mass General Brigham Medicare Advantage plan drops Dana-Farber Cancer Hospital¶
Dana-Farber Cancer Hospital was dropped from Mass General Brigham's Medicare Advantage network following the health systems' earlier split.
Sources: STAT News RSS
5 Experts retain hope in alternative therapies after Angelman syndrome drug failure¶
Following the failure of an experimental Angelman syndrome treatment, researchers remained optimistic about prospects for similar candidate therapies.
Sources: STAT News RSS